Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Doxorubicin (Dox) is a commonly used chemotherapeutic drug in human colon cancer. However, it becomes increasingly ineffective with tumor progression, the underlying mechanism of which remains to be elucidated. Emerging evidence has led to the identification of an association between chemoresistance and the acquisition of epithelial-mesenchymal transition (EMT) in cancer. However, it remains to be elucidated whether this process is involved in the development of resistance to Dox in colon cancer. In HCT116 human colon cancer cells treated with Dox (50 nmol/l), EMT was induced, and transforming growth factor (TGF)β signaling and multi-drug resistant plasma membrane glycoprotein levels were significantly increased. By contrast, silencing of Smad4, using stable RNA interference, inhibited TGFβ signaling, reversed the process of EMT and markedly increased the sensitivity of HCT116 cells to Dox. The results of the present study suggested that the combination of Dox with the downregulation of TGFβ signaling may be a potential novel therapeutic strategy with which to overcome chemoresistance during colon cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“Patients who are initially refractory to therapy exhibit intrinsic drug resistance, while patients who relapse following an initial response to the therapy, do so as a result of acquired drug resistance (14).”
BackgroundSASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells
Canino, C., Mori, F., Cambria, A., Diamantini, A., Germoni, S., Alessandrini, G., Borsellino, G., Galati, R., Battistini, L., Blandino, R., et al. (2012) · Oncogene · doi:10.1038/onc.2011.485 · Cited by 200 · cited 1×
“During the development of drug resistance, reversible epigenetic changes indicate alterations in the differentiation state of the tumor, which are likely to reflect EMT (8).”
BackgroundRosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M. R., Lucidi, A., Ferrandina, G., Natali, P. G., & Bagnato, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2325 · Cited by 187
Sims, J. T., Ganguly, S. S., Bennett, H., Friend, J. W., Tepe, J., & Plattner, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055509 · Cited by 121
Cited by
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910
“Other signalling pathways implicated in the regulation of stemness phenotypes by the HIFs included the TGF-β, Wnt/β-catenin, TNFα and NF-κB [72–74].”
BackgroundInfluentialTargeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
Wang, L., Cho, K. B., Li, Y., Tao, G., Xie, Z., & Guo, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225758 · Cited by 605
Metadata
- Authors
- LI, J., LIU, H., YU, J., & YU, H.
- Venue
- Molecular Medicine Reports
- Publisher
- Spandidos Publications
- Published
- 2015-02-16
- Volume
- 12
- Issue
- 1
- Pages
- 192-198
- ISSN
- 1791-2997 (ISSN-L)
- 1791-3004
- OpenAlex
- W2092249151
- Cited by
- 90
- References
- 4
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. https://app.cochat.ai/papers/10.3892/mmr.2015.3356
- The paper
- LI, J., LIU, H., YU, J., & YU, H. (2015). Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2015.3356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.